WO2003082882A1 - Derive phospholipidique - Google Patents
Derive phospholipidique Download PDFInfo
- Publication number
- WO2003082882A1 WO2003082882A1 PCT/JP2003/003966 JP0303966W WO03082882A1 WO 2003082882 A1 WO2003082882 A1 WO 2003082882A1 JP 0303966 W JP0303966 W JP 0303966W WO 03082882 A1 WO03082882 A1 WO 03082882A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phospholipid
- group
- compound
- phospholipid derivative
- drug
- Prior art date
Links
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 65
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 125000002252 acyl group Chemical group 0.000 claims abstract description 29
- 125000005702 oxyalkylene group Chemical group 0.000 claims abstract description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 11
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 6
- -1 phospholipid compound Chemical class 0.000 claims description 102
- 150000002632 lipids Chemical class 0.000 claims description 101
- 239000012528 membrane Substances 0.000 claims description 83
- 239000003814 drug Substances 0.000 claims description 63
- 229940079593 drug Drugs 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 38
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 19
- 239000003960 organic solvent Substances 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000002502 liposome Substances 0.000 abstract description 12
- 239000002537 cosmetic Substances 0.000 abstract description 10
- 239000013543 active substance Substances 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 230000003381 solubilizing effect Effects 0.000 abstract description 4
- 238000012377 drug delivery Methods 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 98
- 239000000203 mixture Substances 0.000 description 56
- 239000000243 solution Substances 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 39
- 238000003786 synthesis reaction Methods 0.000 description 39
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 34
- 239000013078 crystal Substances 0.000 description 34
- 239000003125 aqueous solvent Substances 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 239000006185 dispersion Substances 0.000 description 24
- 239000000126 substance Substances 0.000 description 21
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 238000004809 thin layer chromatography Methods 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 239000000839 emulsion Substances 0.000 description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 13
- 239000000693 micelle Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 11
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 11
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000012790 confirmation Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000002270 dispersing agent Substances 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 210000003705 ribosome Anatomy 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 9
- 125000006353 oxyethylene group Chemical group 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 238000005227 gel permeation chromatography Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- NWAGXLBTAPTCPR-UHFFFAOYSA-N 5-(2,5-dioxopyrrolidin-1-yl)oxy-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)ON1C(=O)CCC1=O NWAGXLBTAPTCPR-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 229960004679 doxorubicin Drugs 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- LQIPDFIUPOYMPR-BKYURJJWSA-N (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-[(1s)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide Chemical compound O1[C@@H]([C@@H](O)CO)[C@H](NC(=O)CNC(=O)/C=C/C=C/CCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1NC=N2 LQIPDFIUPOYMPR-BKYURJJWSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- RFWFOJDAIRDAPK-VKHMYHEASA-N (3s)-3-aminooxane-2,6-dione Chemical compound N[C@H]1CCC(=O)OC1=O RFWFOJDAIRDAPK-VKHMYHEASA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LONWRQOYFPYMQD-DTQAZKPQSA-N (e)-n-[6-methoxy-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-2-phenylethenesulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OC)=C1NS(=O)(=O)\C=C\C1=CC=CC=C1 LONWRQOYFPYMQD-DTQAZKPQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 1
- 108010062075 20-O-(Nalpha-(4-(3-O-methylfucopyranosyloxy)phenylaminothiocarbonyl)histidylvalyl)camptothecin Proteins 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- GGPPBTSXFROGAE-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile Chemical compound C1=CC(Br)=CC=C1CN(N1C=NN=C1)C1=CC=C(C#N)C=C1 GGPPBTSXFROGAE-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical group CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical class OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 235000010044 Hernandia moerenhoutiana Nutrition 0.000 description 1
- 244000084296 Hernandia moerenhoutiana Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- NDDPLBMQWXXSHQ-UHFFFAOYSA-N ON(C1=C(C=CC=C2)C2=C2)NN=C1C2=O Chemical compound ON(C1=C(C=CC=C2)C2=C2)NN=C1C2=O NDDPLBMQWXXSHQ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000382928 Oxya Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
- GMJWGJSDPOAZTP-MIDYMNAOSA-N bms-188797 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 GMJWGJSDPOAZTP-MIDYMNAOSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- LGCWOEYDVKIVCX-UHFFFAOYSA-N carbonic acid;pyrrolidine-2,5-dione Chemical compound OC(O)=O.O=C1CCC(=O)N1.O=C1CCC(=O)N1 LGCWOEYDVKIVCX-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- RPEWULDFOYJQLR-XYQXTPBESA-N chembl298802 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](OC(=O)\C=C\C=4C=CC(=CC=4)C(=O)C=4C=CC=CC=4)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)C)C(=O)C1=CC=CC=C1 RPEWULDFOYJQLR-XYQXTPBESA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- POADTFBBIXOWFJ-VWLOTQADSA-N cositecan Chemical compound C1=CC=C2C(CC[Si](C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 POADTFBBIXOWFJ-VWLOTQADSA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical group CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- XAKLYHGHEFMDAP-IAXKEJLGSA-N drf-1042 Chemical compound C1=CC=C2C=C(C(OCCO)N3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 XAKLYHGHEFMDAP-IAXKEJLGSA-N 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
- 229950009429 exatecan Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000002194 freeze distillation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- QZUHFMXJZOUZFI-ZQHSETAFSA-N miproxifene phosphate Chemical compound C=1C=C(C(C)C)C=CC=1C(/CC)=C(C=1C=CC(OP(O)(O)=O)=CC=1)\C1=CC=C(OCCN(C)C)C=C1 QZUHFMXJZOUZFI-ZQHSETAFSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- OCKHRKSTDPOHEN-BQYQJAHWSA-N n-(4-methoxyphenyl)sulfonyl-n-[2-[(e)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C)=O)C1=CC=CC=C1\C=C\C1=CC=[N+]([O-])C=C1 OCKHRKSTDPOHEN-BQYQJAHWSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- LBGFKUUHOPIEMA-PEARBKPGSA-N sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000017454 sodium diacetate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/556—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
- C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
- C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
- C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
- C08G65/3353—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus
Definitions
- the present invention relates to a phospholipid derivative containing a branched polyalkylene oxide and a method for producing the same.
- the present invention also relates to a surfactant, a solubilizer, a cosmetic dispersant, and a lipid membrane structure containing the phospholipid derivative.
- particulate drug carriers such as liposome preparations and polypeptides such as protein preparations have poor retentivity in blood, and cause reticuloendothelial system tissues such as liver and spleen.
- RES reticuloendothelial system tissues
- the presence of RES has led to the development of targeted drug carriers, which deliver drugs to organs other than RES, and microparticulate drug carriers as sustained release drugs, which control drug release by retaining the drug in the blood for a long time. This is a major obstacle to its use.
- glycolipids For example, glycophone (Abstracts of the 106th Annual Meeting of the Pharmaceutical Society of Japan, 336 pages, 1986), ganglioside GM1 (FEBS letter, 223 volumes, 42 pages, 1987), phosphatidylinositol (FEBS letters, 223 volumes, 42 1987), Glycophon and Gandarioside GM 3 (Japanese Patent Application Laid-Open No.
- two water-soluble polymers are introduced using triazine to reduce the number of bonding points and increase the amount of active groups such as lysine residues in the polypeptide.
- active groups such as lysine residues in the polypeptide.
- ribosome preparations there are reports that two water-soluble polymers were introduced into triazine and used to modify the liposome surface in order to increase the molecular weight of the water-soluble polymer. This modification is limited to two. In this case, it is considered that the effect of imparting microcirculation to the liposome surface is smaller than that in the case of having a hydrophilic group.
- phospholipid derivatives containing polyalkylene oxide groups are also used as surfactants, but none have been known that are highly safe for living organisms and can be used stably under high salt concentration conditions. . Disclosure of the invention
- An object of the present invention is to provide a novel phospholipid derivative containing a polyalkylene oxide. Is to do. More specifically, the present invention provides a phospholipid derivative which is highly safe for a living body and can be suitably used in the field of solubilization and dispersion of a physiologically active substance or the like, or drug delivery system such as ribosome or cosmetics. It is an object of the present invention to do so.
- the present inventors have made intensive studies to solve the above problems, and as a result, have succeeded in providing a novel phospholipid derivative represented by the following general formula and a method for producing the same.
- Z represents a residue of a compound having 3 to 10 hydroxyl groups; AO represents an oxyalkylene group having 2 to 4 carbon atoms; RiCO and R 2 CO independently represent 8 to 22 carbon atoms.
- X represents a hydrogen atom, an alkali metal atom, an ammonium or an organic ammonium; a represents an integer of 0 to 4; b represents 0 or 1; Q represents a hydrogen atom or a methyl group.
- m represents the average number of moles of the oxyalkylene group added;
- m, k1, k2, and k3 represent the following conditions: 3 ⁇ m ⁇ 200, 9 ⁇ mX (k1 + k2 + k 3) ⁇ 1000, 1 ⁇ k 1 ⁇ 2, 0 ⁇ k 2 ⁇ 9, and 0 ⁇ k 3 ⁇ 9 and 3 ⁇ k 1 + k 2 + k 3 ⁇ 10)
- the present invention provides a phospholipid derivative represented by the formula: +
- the above 4 kl + k 2 + k 3 ⁇ 8 A phospholipid derivative wherein WCC) and R 2 CO are each independently an acyl group having 12 to 20 carbon atoms; a phospholipid derivative wherein k 2 is 0; There is provided the above phospholipid derivative wherein b is 0; and the above phospholipid derivative wherein k3> 1 and k2> k3.
- the present invention provides a surfactant comprising a phospholipid derivative represented by the above general formula (1); a solubilizer comprising a phospholipid derivative represented by the above general formula (1)
- a dispersant containing the phospholipid derivative represented by the general formula (1) preferably a cosmetic dispersant; a lipid membrane structure containing the phospholipid derivative represented by the general formula (1), preferably Is provided with ribosomes.
- R 1 and R 2 each independently represent a hydrocarbon group having 8 to 22 carbon atoms; R 3 represents a divalent hydrocarbon group having 2 to 4 carbon atoms; X represents a hydrogen atom; A represents an integer of 0 to 4; Y represents a hydrogen atom or N-hydroxysuccinimide.
- Step A represents a residue of a compound having 3 to 10 hydroxyl groups; AO represents one or more of oxyalkylene groups having 2 to 4 carbon atoms, and two or more oxyalkylenes When it represents a group, it may be in a block form or a random form; m represents the average number of moles of the oxyalkylene group; m and k represent the following conditions: 3 ⁇ m ⁇ 200, 9 ⁇ m X is a number satisfying k ⁇ 1000 and 3 ⁇ k ⁇ 10) in an organic solvent in the presence of a basic catalyst (hereinafter referred to as "Step A”) May be provided.
- This method can be carried out preferably at a temperature in the range of 20 to 90 ° C., and is preferably carried out in the presence of a dehydrating condensing agent.
- the present invention provides a method for producing a phospholipid derivative represented by the above general formula (1), which comprises the following general formula (4):
- Y represents a hydrogen atom or N-hydroxysuccinimide
- k4 and k5 are as follows: l ⁇ k4 ⁇ 10, 0 ⁇ k5 ⁇ 9, 3 ⁇ k4 + k5 ⁇ 10
- a method is also provided which comprises a step of reacting a crystalline derivative with an organic solvent in the presence of a basic catalyst. This method can be preferably carried out in the range of 20 to 90 ° C.
- Z is a residue of a compound having 3 to 10 hydroxyl groups.
- the type of the compound having 3 to 10 hydroxyl groups is not particularly limited, and examples thereof include glycerin, diglycerin, pentaerythritol, triglycerin, tetraglycerin, pentaglycerin, hexaglycerin, heptaglycerin, and octaglycerin. Of the polyglycerin compounds.
- the residue of the compound having 3 to 10 hydroxyl groups refers to the total number of branches (k 1 + k 2 + k 3) represented by k 1, k 2, and k 3 from the compound. ) Means the remaining part excluding the hydroxyl group.
- kl + k2 + k3 corresponds to the number of branches of Z, and is an integer in the range of 3 to 10, preferably 3 to 8, and more preferably 4 to 8.
- the numerical range indicated by “to” is a range including the upper and lower numerical values). If the number of branches is less than 3, the desired effect of the compound may not be achieved. If the number of branches is greater than 10, the viscosity of a branched material represented by polyglycerin or the like increases, making handling difficult. In some cases, and it may be difficult to obtain raw materials.
- kl is the number of the partial structure containing the residue of the phospholipid compound represented by the formula (2) bonded to the residue represented by Z, and is 1 or 2.
- the number of partial structures containing the above phospholipid compound When the number of partial structures containing the above phospholipid compound is 0, it is difficult to stably bind to liposomes or other lipid bilayers due to the absence of a hydrophobic binding portion, making it difficult to modify the liposome membrane. It is. When the number of the partial structures containing the above phospholipid compound is larger than 2, the number of phospholipid residues contained in one molecule is large, and the hydrophobic bond to the liposome membrane is increased. In some cases, the desired effect of the compound of the present invention may not be obtained.
- R 1 CO and R 2 CO each independently have 8 to 24 carbon atoms, preferably 12 to 20; More preferably, it represents 14 to 18 acyl groups.
- the type of the acyl group is not particularly limited, and any of an aliphatic acyl group and an aromatic acyl group may be used. Usually, an acyl group derived from a fatty acid can be preferably used.
- I ⁇ as CO and R 2 CO specific ones for example the force prills acid, force purine acid, lauric acid, myristic acid, Pa palmitic acid, palmitic train acid, stearic acid, isostearic acid, Orein acid, linoleic acid, Examples thereof include an acyl group derived from a saturated or unsaturated linear or branched fatty acid such as araquinic acid, behenic acid, erlic acid, and lignoceric acid.
- O and R 2 CO may be the same or different. If the number of carbon atoms exceeds 24, the dispersion in the aqueous phase may be poor and the reactivity may decrease.
- k2 indicates the number of the partial structure represented by one COOX at the terminal bound to the residue represented by Z, and is selected from the range of 0-9. When it is 0, it means that the compound of the present invention has substantially no partial structure represented by COOX at the end.
- X represents a hydrogen atom, an alkali metal atom, an ammonium, or an organic ammonium, and is preferably a hydrogen atom or an alkali metal atom. Specific examples thereof include sodium and potassium as alkali metal atoms, and triethylammonium as organic ammonium.
- k3 represents the number of the partial structure having a hydroxyl group or a methyl group at the terminal bonded to the residue represented by Z, and is selected from the range of 0-9.
- Q is a hydrogen atom or a methyl group.
- the compound of the present invention may lose its hydrophilicity.
- b is an integer of 0 or 1
- a is preferably an integer of 1 to 4, and more preferably a is 2 or 3.
- a is preferably 1 or 0, and more preferably a is 0.
- the oxyalkylene group represented by AO is an oxyalkylene group having 2 to 4 carbon atoms, preferably 2 or 3, and examples thereof include an oxyethylene group, an oxypropylene group, an oxytrimethylene group, and an oxybutylene group. . Of these, oxy An ethylene group and an oxypropylene group are preferred, and an oxyethylene group is particularly preferred.
- the polyoxyalkylene group represented by one (AO) ra — may be composed of only one oxyalkylene group, or may be a combination of two or more oxyalkylene groups. When two or more oxyalkylene groups are combined, the method of combination is not particularly limited, and the polyoxyalkylene group may be block-shaped or random. When the ratio of oxyethylene groups to all oxyalkylene groups is low, the water solubility may decrease, so that the ratio of oxyethylene groups to all oxyalkylene groups is preferably 50 to 100 mol%.
- m represents an average number of added moles of the oxyalkylene group, and is a number of 3 to 200, preferably 7 to 80. If m is less than 3, the desired effect may be reduced when the phospholipid derivative of the present invention is used in a drug delivery system. On the other hand, when it is larger than 200, the reactivity between the phospholipid compound represented by the formula (2) and the polyalkylene oxide compound represented by the formula (3) during the production of the phospholipid derivative of the present invention. The viscosity may decrease, and the viscosity of the polyalkylene oxide compound represented by the formula (3) may increase and the workability may decrease.
- m means the number of oxyalkylene groups contained in the polyoxyalkylene groups present in the [kl + k2 + k3] individual branches present in the compound of the present invention.
- m X [k 1 + k 2 + k 3] means the number of oxyalkylene groups contained in the entire compound of the present invention, and is 9 to 100, preferably 20 to 700, more preferably Is a number from 30 to 350.
- the method for producing the compound of the present invention represented by the formula (1) is not particularly limited, but a phospholipid derivative in which k 2 is 0 can be produced, for example, in step A with high purity.
- R R and a are the same as those described in the formula (1), and Y is a hydrogen atom or N-hydroxysuccinimide.
- the phospholipid compound represented by the formula (2) can be produced by a known method. For example, as described later, it can be easily produced by reacting a phospholipid compound with a dicarboxylic anhydride.
- the phospholipids used can be natural phospholipids. It may be a synthetic phospholipid, and examples thereof include natural and synthetic phosphatidylethanolamines such as soybean and soybean hydrogenated phosphatidyldiethanolamine, egg yolk and egg yolk hydrogenated phosphatidyldiethanolamine.
- Z, A O and m are the same as those described in the formula (1). It corresponds to the sum of kl, k2, and k3 described in Equation (1).
- the reaction between the phospholipid compound represented by the formula (2) and the polyalkylene oxide compound represented by the formula (3) can be carried out in an organic solvent in the presence of a basic catalyst. This can be done using.
- the type of the basic catalyst is not particularly limited.
- nitrogen-containing substances include triethylamine, pyridine, dimethylaminopyridine, ammonium acetate, and the like
- organic salts include sodium phosphate, sodium carbonate, sodium hydrogen carbonate, and boron. Examples thereof include sodium acid and sodium acetate.
- the amount of the basic catalyst is, for example, 1.5 to 10 times, preferably 2 to 5 times the mole of the polyalkylene oxide compound represented by the formula (2).
- the organic solvent any solvent having no reactive functional group such as a hydroxyl group can be used without any particular limitation. Examples include ethyl acetate, dichloromethane, chloroform, benzene and toluene. Of these, chloroform and toluene are preferred.
- An organic solvent having a hydroxyl group such as ethanol may react with a terminal carboxyl group of the polyalkylene oxide compound represented by the formula (2).
- a dehydrating condensing agent When a dehydrating condensing agent is used, there is no particular limitation as long as the dehydrating condensing agent is capable of dehydrating and condensing the carbonyl group of the polyalkylene oxide compound represented by the formula (3) with the functional group of the phospholipid represented by the formula (2). Can be used. Examples of such a dehydrating condensing agent include carbodiimide derivatives such as dicyclohexylcarbodiimide, and dicyclohexylcarbodiimide is particularly preferred.
- the amount of the dehydrating condensing agent used is, for example, 1.05 to 5 times, preferably 1.5 to 2.5 times the mol of the polyalkylene oxide compound represented by the formula (3). N-Hydroxysuccinic acid imide In some cases, the yield can be increased by adding 0.1 to 2 times mol of the polyalkylene oxide compound represented by the formula (3) in the reaction system.
- the reaction temperature of step (A) is usually in the range of 20 to 90 ° C, preferably 40 to 80 ° C.
- the reaction time is 1 hour or more, preferably 2 to 8 hours.
- the reaction rate is low, and at a temperature higher than 90 ° C, the acyl group of the phospholipid compound represented by the formula (2) used for the reaction may be hydrolyzed.
- the compound represented by the formula (1) of the present invention is obtained by reacting an activated ester derivative of a phospholipid compound represented by the formula (2) with a polyalkylene oxide compound represented by the formula (3). Can also be manufactured.
- the activated ester derivative can be obtained, for example, by reacting a phospholipid compound represented by the formula (2) with an activating agent in the presence of a dehydrating condensing agent.
- the type of the above-mentioned activator is not particularly limited.
- ⁇ -hydroxysuccinimide is preferred.
- the reaction between the phospholipid compound represented by the formula (2) and the activator is carried out in the same manner as the reaction with the dicarboxylic acid anhydride, in the presence of a dehydrating condensing agent and does not react with the carboxylic acid, for example, chloroform, toluene.
- the reaction can be carried out at a reaction temperature of 15 to 80 ° C., preferably 25 to 55 ° C., for example, by dispersing the activator in a solution of the polyalkylene oxide compound and stirring. Can be performed.
- N-hydroxysuccinimide when N-hydroxysuccinimide is used as the activator, the carboxyl group of the phospholipid compound represented by the formula (2) reacts with the imide group of N-hydroxysuccinimide, An activated ester derivative in which N-hydroxysuccinimide is bound to the carboxyl group end of the phospholipid compound represented by (2) is obtained.
- a phospholipid derivative in which k 2 is not 0, that is, a branched oxya Compounds having a partial structure in which the carboxyl group terminal is a carboxyl group are represented by the above general formula
- the polyalkylene oxide derivative represented by (4) and the phospholipid derivative represented by the above general formula (5) are produced in high purity by reacting in an organic solvent in the presence of a basic catalyst. Can be.
- the organic solvent used for the reaction can be used without any particular limitation as long as it does not have a reactive functional group such as a hydroxyl group.
- a reactive functional group such as a hydroxyl group. Examples include ethyl acetate, dichloromethane, chlorophonolem, benzene and toluene. Of these, chlorophonolene and toluene are preferred.
- An organic solvent having a hydroxyl group, such as ethanol, may react with the terminal hydroxyl group of the polyalkylene oxide compound represented by the formula (4).
- the type of the basic catalyst used in the reaction is not particularly limited.
- the nitrogen-containing substance include triethylamine and ammonium acetate
- the organic salts include sodium phosphate, sodium carbonate, sodium hydrogencarbonate, sodium borate and sodium borate. And sodium acetate.
- the amount of the basic catalyst is, for example, 1.5 to 10 times, preferably 2 to 7 times the mole of the polyalkylene oxide compound represented by the formula (4).
- the reaction temperature is usually from 20 to 90 ° C, preferably from 40 to 80 ° C.
- the reaction time is 1 hour or more, preferably 2 to 8 hours.
- the reaction rate may be low, and at a temperature higher than 90 ° C, the acyl group of the phospholipid compound represented by the formula (5) used in the reaction may be hydrolyzed.
- the compound of the present invention may be obtained as a single compound by synthesis, or kl, k2, and k3 may be obtained as different mixtures. Such a mixture is also included in the scope of the present invention.
- a solubilizing solution, an emulsion and a dispersion can be obtained.
- the surfactant of the present invention is used as an emulsifier, solubilizer or dispersant
- the emulsifier, solubilizer or dispersant may use only the surfactant of the present invention. Alternatively, it may contain other known components used for dispersion.
- Solubilization or dispersion form The method is not limited, and examples thereof include a solution in which a fat-soluble substance or the like is dissolved in a dispersion medium such as water or a buffer, and a dispersion in which a fat-soluble substance or the like is dispersed in a dispersion medium such as water or a buffer.
- the form of the emulsion or solubilizing solution is not limited, and may be a micelle solution formed by the surfactant of the present invention, that is, a micelle solution containing a fat-soluble substance therein, or a dispersion medium such as water or a buffer solution.
- a micelle solution formed by the surfactant of the present invention, that is, a micelle solution containing a fat-soluble substance therein, or a dispersion medium such as water or a buffer solution.
- An emulsion solution in which the dispersed particles of the surfactant and the fat-soluble substance of the present invention are present as colloidal particles or larger particles are exemplified.
- the micelle solution include those having a dispersed particle diameter of 10 to 300 nm, particularly as a polymer micelle solution.
- the emulsion solution may be an O / W type in which a fat-soluble substance is blended in an oil phase or a W / OZW type in which a fat-soluble substance is blended in an aqueous phase.
- the fat-soluble substance which can be solubilized or emulsified is not particularly limited. And the like.
- the form of use as a dispersant in the field of cosmetics is not particularly limited.For example, a water-soluble substance such as ascorbic acid is retained in the internal aqueous phase of the lipid membrane structure, or a fat-soluble substance such as tocopherol is used as a lipid duplex.
- the target substance can be more stably dispersed in an aqueous solution.
- the amount of addition is 0.1 to 20% by weight, preferably 0.5 to 7% by weight, based on the total weight of the substances to be solubilized, dispersed, emulsified, and the like. And more preferably 0.5 to 5% by weight.
- the compound in which k 2 is 0 in the above general formula (1) can be effectively used as a nonionic surfactant particularly under high salt concentration conditions.
- polyalkylene oxide-modified phospholipids and the like can be used as a surfactant because they have hydrophilicity derived from an oxyalkylene group and hydrophobicity derived from an acyl group.
- it is usually oxoa typified by polyalkylene oxide-modified phospholipids.
- Surfactants with alkylene groups produce turbidity when used under high salt conditions. There is a problem.
- the compound in which Q is a hydrogen atom in the above general formula (1) is characterized in that it can maintain a high solubilizing ability even in a high salt concentration state, and can be used as a surfactant having excellent salt resistance. Further, it can be used as a surfactant having high compatibility with skin in the field of cosmetics.
- a compound having k 3 ⁇ 1 and k 2> k 3 that is, a compound having a carboxyl group at the terminal of a branched oxyalkylene group, may be used as a pH-sensitive phospholipid. It can be used as an agent.
- a cationic substance for example, a cationic physiologically active substance
- a basic substance for example, coating the surface of fine particles containing a cation or a basic substance with the above compound Thereby, it can be stably dispersed in water. Since the compound of the present invention has a polyanionic group, it can be stably dispersed by ionic bonding.
- k 3 is preferably less than 1.
- the compound of the present invention represented by the above general formula (1) can be used as a constituent phospholipid of a lipid membrane structure such as ribosome, emulsion, micelle or the like.
- a lipid membrane structure such as ribosome, emulsion, micelle or the like.
- the residence time of a lipid membrane structure, preferably a ribosome, in blood can be increased. This effect can be achieved by adding a small amount of the compound of the present invention to the lipid membrane structure.
- the use of the compound of the present invention having three or more hyperbranches as a constituent phospholipid of the lipid membrane structure allows the polyoxyethylene chain to form the membrane of the lipid membrane structure.
- the compounding amount of the compound of the present invention in the lipid membrane structure can improve the efficacy of a drug in vivo. It is sufficient that the amount is sufficient for expression, and there is no particular limitation. For example, it can be appropriately selected according to the type of the drug to be retained in the lipid membrane structure, the use for treatment or prevention, the form of the lipid membrane structure, and the like.
- the type of drug held by the lipid membrane structure provided by the present invention is not particularly limited, but for example, a compound used as an antitumor agent is preferable.
- These compounds include, for example, irinotecan hydrochloride, nogitecan hydrochloride, exatecan, RFS-2000, Lu rtotecan, BNP-1350, Bay-383441, PNU-166148, I DEC_132, BN-80915, DB_38, DB-81, DB — 90, DB_91, CKD-620, T-1128, ST-1480, ST-1481, DRF-1042, DE-310 and other camptothecin derivatives, docetaxel hydrate, and the like.
- Taxane derivatives such as clitaxel, IND-5109, BMS-184476, BMS-188797, T-3782, TAX-1011, SB-RA-31012, SBT-1514, DJ-927, diphosphamide, dimustine hydrochloride, carbocon , Cyclophosphamide, dacarbazine, thiotepa, busulfan, me / refharan, lanmustine, estramustine sodium phosphate, 61-mercaptopurine liposide, enositabine, gemcitabine hydrochloride, carmofur, cytarabine, cytarabine otafos de doxate, tigafulin , Hydroxycarbamide, Fluorouracil, Methotrexate, Mercaptopurine, Fludarabine phosphate, Actinomycin D, Aclarubicin hydrochloride, Idarubicin hydrochloride, Evirubicin hydrochlor
- the lipid membrane structure of the present invention may include a gene or the like.
- the gene may be any of oligonucleotide, DNA and RNA, and particularly a gene for in vitro transfection or a gene that acts upon expression in in vitro, such as a gene for gene therapy.
- genes used for breeding industrial animals such as experimental animals and livestock.
- Examples of the gene for gene therapy include a gene encoding a physiologically active substance such as an antisense oligonucleotide, an antisense DNA, an antisense RNA, an enzyme, and a cytokin.
- the lipid membrane structure further includes sterols such as phospholipids, cholesterol monoles, cholestano monoles, and other saturated and unsaturated acyl groups having 8 to 22 carbon atoms.
- sterols such as phospholipids, cholesterol monoles, cholestano monoles, and other saturated and unsaturated acyl groups having 8 to 22 carbon atoms.
- an antioxidant such as ⁇ -tocopherol.
- Phospholipids include phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidinoregylglycerolene, cardiolipin, sphingomyelin, ceramidophosphorinoleetanolenoamine, ceramidophosphorylglycerol, ceramidophosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphorylphosphoryl
- the fatty acid residues of these phospholipids are not particularly limited, but include, for example, saturated or unsaturated fatty acid residues having 12 to 20 carbon atoms.
- lauric acid, myristic acid examples include an acyl group derived from a fatty acid such as palmitic acid, stearic acid, oleic acid, and linoleic acid.
- phospholipids derived from natural products such as egg yolk lecithin and soybean lecithin can also be used.
- the form of the lipid membrane structure containing the compound of the present invention and the production method thereof are not particularly limited.
- examples of the existing form include a dried lipid mixture form, a form dispersed in an aqueous solvent, a dried form thereof, a frozen form thereof, and the like.
- a dried lipid mixture for example, it must be prepared by dissolving the lipid components to be used in an organic solvent such as chloroform, and then drying under reduced pressure using an evaporator or spray drying using a spray dryer. Can be.
- Examples of the form in which the lipid membrane structure is dispersed in an aqueous solvent include monolamellar ribosomes, multilayer ribosomes, w-emulsions, w / oZw-emulsions, spherical micelles, string micelles, and irregular layered structures. Among them, ribosomes are preferred.
- the size of the dispersed lipid membrane structure is not particularly limited.For example, in the case of liposome-emulsion, the particle size is 50 nm to 5 m, and in the case of spherical micelles, the particle size is 5 nm. From 100 nm. In the case of string-like micelles or irregular layered structures, the thickness of each layer can be considered to be 5 to 10 nm and these layers are formed.
- the composition of the aqueous solvent is not particularly limited, and examples thereof include buffers such as phosphate buffer, citrate buffer, and phosphate buffered saline, physiological saline, and a medium for cell culture. You may.
- buffers such as phosphate buffer, citrate buffer, and phosphate buffered saline, physiological saline, and a medium for cell culture. You may.
- the compound of the present invention is used in an aqueous solvent, the lipid membrane structure can be stably dispersed, but in addition to water, an aqueous sugar solution such as glucose, lactose, and sucrose, glycerin, propylene glycol, and the like can be used.
- a polyhydric alcohol aqueous solution or the like may be added.
- the electrolyte in the aqueous solvent from the viewpoint of physical stability such as aggregation.
- the pH of the aqueous solvent from weakly acidic to near neutral (pH 3.0 to 8.0), and to remove dissolved oxygen by nitrogen bubbling. desirable.
- an effective storage is possible by using an aqueous sugar solution and an aqueous polyhydric alcohol solution, respectively.
- the concentration of these aqueous solvents is not particularly limited.
- the concentration is preferably 2 to 20% (W / V), and more preferably 5 to 10% (W / V). .
- the content is preferably 1 to 5% (W / V), and more preferably 2 to 2.5% (W / V).
- the concentration of the buffer is preferably 5 to 5 OmM, more preferably 10 to 2 OmM.
- the concentration of the lipid membrane structure in the aqueous solvent is not particularly limited, but the concentration of the total lipid in the lipid membrane structure is preferably from 0.1 mM to 50 OmM, more preferably from 1 mM to 10 OmM. .
- the form in which the lipid membrane structure is dispersed in an aqueous solvent is manufactured by adding the above-mentioned dried lipid mixture to the aqueous solvent, and further emulsifying the mixture with an emulsifier such as a homogenizer, an ultrasonic emulsifier, a high-pressure jet emulsifier, or the like.
- an emulsifier such as a homogenizer, an ultrasonic emulsifier, a high-pressure jet emulsifier, or the like.
- the ribosome can be produced by a well-known method, for example, a reverse phase evaporation method, and the method is not particularly limited.
- extrusion extrusion (extrusion filtration) may be performed under high pressure using a membrane filter having a uniform pore diameter.
- Examples of the method for further drying the lipid membrane structure dispersed in the aqueous solvent include usual freeze-drying and spray-drying.
- an aqueous saccharide solution preferably an aqueous sucrose solution and an aqueous lactose solution may be used as described above.
- the lipid membrane structure can be stored for a long period of time.
- efficiency can be improved. Since the lipid mixture is well hydrated, there is an advantage that the drug can be efficiently held in the lipid membrane structure.
- a pharmaceutical composition can be produced by adding a drug to the lipid membrane structure, and the lipid membrane structure can be used as a pharmaceutical composition for treating and / or preventing a disease.
- the drug is a gene, it can be used as a gene transfer kit.
- the form of the pharmaceutical composition may be a form in which the lipid membrane structure and the medicine are mixed, or a form in which the medicine is held in the lipid membrane structure.
- retention means that the drug is present in the membrane of the lipid membrane structure, on the surface, inside, in the lipid layer, and on the surface of the lipid or lipid layer.
- the existence form of the pharmaceutical composition and the method for producing the same are not particularly limited as in the case of the lipid membrane structure.
- the form includes a form dispersed in an aqueous solvent, a dried form and a frozen form.
- the mixed dried product of lipids and medicine is prepared by, for example, dissolving the lipid components to be used and the medicine in an organic solvent such as chloroform, and then drying the mixture under reduced pressure using an evaporator and drying using a spray dryer.
- an organic solvent such as chloroform
- Examples of the form in which the mixture of the lipid membrane structure and the drug are dispersed in an aqueous solvent include multilayer liposomes, monolayer ribosomes, o / w type emulsions, wZo / w type emulsions, spherical micelles, string micelles, Examples include an amorphous layered structure, but there is no particular limitation.
- the size (particle size) of the mixture and the composition of the aqueous solvent are not particularly limited. For example, 50 nm to 2 ⁇ m for ribosomes and 5 to 100 nm for spherical micelles 5 0 ⁇ ⁇ when forming emulsions! ⁇ 5 ⁇ .
- the concentration in the aqueous solvent as a mixture is not particularly limited. There are several known methods for producing a mixture of a lipid membrane structure and a drug in an aqueous solvent, and the method generally depends on the mode of existence of the mixture of the lipid membrane structure and the drug. It is necessary to select an appropriate manufacturing method as described below. Manufacturing method 1
- This method involves dissolving the lipid components once in an organic solvent and then emulsifying the dried product from which the organic solvent has been distilled off by adding an aqueous solvent containing a drug to the dried product. If you want to control the size (particle size), you can use a membrane filter with a uniform pore size to perform extrusion under high pressure. It is difficult to dissolve in organic solvents, but can be applied to drugs that dissolve in aqueous solvents. When the lipid membrane structure is a ribosome, there is an advantage that the drug can be retained in the inner aqueous phase. Manufacturing method 3
- a lipid membrane structure such as ribosome, emulsion, micelle, or layered structure already dispersed in the aqueous solvent.
- the application of this method is limited to water-soluble medicaments. Since this is a method of adding a drug from the outside to a lipid membrane structure that has already been completed, if the drug is a polymer, the drug cannot enter the inside of the lipid membrane structure and the surface of the lipid membrane structure May take the form of existence linked to When ribosome is used as the lipid membrane structure, using this production method 3, a drug takes a sandwich structure (generally called a complex or complex) sandwiched between ribosome particles. It is known.
- the drug is limited to a water-soluble one as in Production method 3.
- the major difference from Production Method 3 lies in the mode of existence of the lipid membrane structure and the drug. That is, in this production method 4, a dried product is produced by temporarily producing a lipid membrane structure dispersed in an aqueous solvent and then drying it. At this stage, the lipid membrane structure exists in a solid state as a fragment of the lipid membrane for fabrication.
- an aqueous saccharide solution preferably, an aqueous solution of bran or lactose
- the lipid membrane fragments that existed in the solid state immediately begin to hydrate with the intrusion of water, and the lipid membrane structure can be reconstituted. At this time, a structure in which the drug is held inside the lipid membrane structure can be produced.
- the production method 3 when the drug is a polymer, the drug cannot enter the lipid membrane structure and takes a mode of being bonded to the surface of the lipid membrane structure, but the production method 4 is large in this point. Is different.
- this production method 4 since the aqueous dispersion of the lipid membrane structure alone is produced in advance, there is no need to consider the decomposition of the drug during emulsification, and the size (particle size) can be easily controlled. It is relatively easy to manufacture compared to Method 1 and Manufacturing Method 2. In addition, since freeze-drying or spray-drying is performed, it is easy to ensure the storage stability of the preparation, and the size (particle size) can be restored even if the dried preparation is rehydrated with an aqueous pharmaceutical solution. The advantages are that, even in the case of a high molecular drug, the drug can be easily held inside the lipid membrane structure.
- a well-known method for producing ribosomes for example, a reverse-phase evaporation method or the like may be used separately. If you want to control the size (particle size), use a membrane filter with a more uniform pore size and perform the extrusion under high pressure. Further, as a method for further drying the dispersion in which the mixture of the lipid membrane structure and the drug is dispersed in an aqueous solvent, freeze-drying and spray-drying can be mentioned.
- an aqueous saccharide solution preferably an aqueous sucrose solution or an aqueous lactose solution
- a normal freezing method can be used.
- an aqueous saccharide solution or an aqueous polyhydric alcohol solution may be used.
- the lipid that can be incorporated in the pharmaceutical composition may be appropriately selected depending on the type of the drug to be used and the like. For example, when the drug is not a gene, 0.1 to 100 parts by weight of the drug is used.
- the medicament is a gene may be a pharmaceutical (genes) 1 / zg, 5 0 0 nmo 1 is preferably from 1, preferably more 1 0 2 0 0 nmo 1 p
- the method of using the compound and the pharmaceutical composition of the present invention may be appropriately determined according to the form of use.
- Means of administration to humans and the like is not particularly limited, and may be oral administration or parenteral administration.
- Oral dosage forms include, for example, tablets, powders, granules, syrups, capsules, and oral liquids.
- Parenteral dosage forms include, for example, injections, drops, Examples include eye drops, ointments, suppositories, suspensions, cataplasms, lotions, azones, plasters and the like.
- injections and infusions are preferred among these, and administration methods include intravenous injection, subcutaneous injection, intradermal injection, and local injection into target cells or organs. .
- the forms of cosmetics include lotions, creams, lotions, emulsions, foams, foundations, lipsticks, packs, skin cleansers, shampoos, rinses, and conditioners. , Hair tonic, hair liquid, hair cream and the like.
- the means for administering the medicament and the composition is not particularly limited, and may be oral administration or parenteral administration, but parenteral administration is preferred.
- the form of the pharmaceutical composition is not particularly limited.
- Examples of the dosage form for oral administration include tablets, powders, granules, and syrups.
- Examples of the dosage form for parenteral administration include: Examples include injections, drops, eye drops, ointments, suppositories and the like. Of these, injections and infusions are preferred, and the administration method is preferably intravenous injection or local injection into target cells or organs.
- Polyoxyethylene penta-risthritol ether (average molecular weight 2000) —Synthesis of monodistearoylphosphadylethanolamine succinate Preparation of distearoylphosphatidylethanolamine succinate
- the progress of the reaction and identification of products were performed by thin-layer chromatography (TLC) using a silica gel plate.
- the developing solvent used was a mixed solvent of chloroform and methanol at a mixing ratio of 85:15 by volume.
- the color was developed with iodine vapor and the content of the substance was determined by comparison with a known amount of a standard substance.
- a spot of polyoxyethylene pentaerythritol ether average molecular weight: 2000
- RfO by binding of the phospholipid compound. Confirmation was carried out by converting to a spot detected in the vicinity of 4-0.5.
- Distearoyl phosphatidylethanolamine succinate obtained in the same manner as in Synthesis Example 1 was dissolved in 1 mL of chloroform and added with triethylamine l O Omg (1 mmo 1). 1.1 g of ethylenehexaglycerol ethereal monodistearoylphosphadylethanolanolamine succinate was obtained.
- the progress of the reaction and identification of the product were performed by thin-layer chromatography (TLC) as in Synthesis 1.
- TLC thin-layer chromatography
- the end point of the reaction is polyoxyethylene hexaglycerol ether (average molecular weight of 20), which is detected near the Rf value of 0.6 to 0.7 by the following TLC.
- the progress of the reaction and identification of the product were performed by thin-layer chromatography (TLC) as in Synthesis 1.
- TLC thin-layer chromatography
- a spot of polyoxyethylene glycerol ether (average molecular weight: 2000), which is detected near the Rf value of 0.6 to 0.7 by the following TLC, has an Rf of 0.4 due to the binding of the phospholipid compound. This was confirmed by conversion to a spot detected at around 0.5.
- the confirmation of the product was confirmed by the fact that the peak of the amino group (3000 cm " 1 ) in phosphatidylethanolamine was changed to a carbonyl group (1700 cm- 1 ) peak by amide bond in the IR spectrum.
- the filtrate was removed by suction filtration, and 1 OmL of hexane was added to the obtained filtrate, and the mixture was cooled to 15 ° C or less to precipitate crystals. These crystals were obtained by filtration. To the obtained crystals, 30 mL of ethyl acetate was added and dissolved by heating to 50 ° C, and then cooled to 15 ° C or lower to precipitate crystals. The crystals were collected by filtration. If there were any insolubles during the heating and dissolution, they were removed by filtration and the process proceeded to the next step.
- the polyoxyethylene pentaerythritol ether used as a raw material had a hydroxyl value of 45 mgKOH / g, and was determined by gel permeation chromatography (GPC) to be polyoxyethylene pentaerythritol ether (molecular weight 5000). Based on the molecular weight of succinimidyl glutarate being 5812, it was confirmed to be a four-branched polyoxyethylene having a molecular weight of about 5,000.
- the GPC is equipped with SHODEX GPC SYSTEM-11 as a system, SHODEX RI-71 as a differential refractometer, and 4 4L SHODEX KF 804 as a column, column temperature 40 ° C, and tetrahydrofuran as a developing solvent.
- the sample was flowed at a flow rate of 1 / min, 0.1 ml of a 0.1% by weight tetrahydrofuran solution of the obtained sample was injected, and the molecular weight was calculated using a BORWI NGPC calculation program.
- Ethyl acetate (3 OmL) was added to the obtained crystals, and the mixture was heated to 50 ° C to dissolve, and then cooled to 15 ° C or lower to precipitate crystals. The crystals were collected by filtration. If there was any insoluble matter during the heating and dissolution, it was removed by filtration and the process proceeded to the next step. The obtained crystals were again dissolved in 2 OmL of ethyl acetate under heating, and 1 OmL of hexane was added. The precipitated crystals were filtered to obtain 5 g of crystals having a final purity of 98%, and the yield was 9%. It was 5%.
- the hydroxyl value of the polyoxyethylene pentaerythritol ether used as the raw material was 26.7 mg KOH / g, and polyoxyethylene pentaerythritol ether (molecular weight 2000) was determined by gel permeation chromatography (GPC). Based on the molecular weight of succinimidyl succinate being 2082, it was confirmed that it was a four-branched polyoxyethylene having a molecular weight of about 2,000.
- GPC has the SHODEX GPC SYSTEM-11, SHOD EX RI-71 as a differential refractometer, three SHODEX KF 804 L columns as columns, and a flow rate of 40 CC, tetrahydrofuran as a developing solvent at a flow rate of lm 1 / min. 0.1 lm 1 of a 0.1% by weight tetrahydrofuran solution was injected, and the molecular weight was calculated using a BORWI NGPC calculation program.
- Example 1 Preparation of lotion (Evaluation as solubilizer)
- a lotion was prepared using the polyoxyethylene pentaerythritol ether (molecular weight: 5,000) glutaryl-monodistearoylphosphatidylethanolamine of Synthesis Example 5. That is, glycerin and propylene glycol were added to purified water of the base material having the composition shown in Table 1 and uniformly dissolved. The other base material was added to ethanol to make it uniform, and then added to the purified aqueous phase while stirring to solubilize it to obtain a lotion.
- the oil phase portion containing the emulsifier of the base material having the composition shown in Table 2 was heated to 60 ° C and uniformly dissolved, and then the aqueous phase portion was added at the same temperature while stirring, and the ribosome was added. An emulsion was obtained.
- Liposomal solution 10.0 w t%
- the product was analyzed by thin-layer chromatography (TLC) using a silica gel plate.
- TLC thin-layer chromatography
- a developing solvent use a mixed solvent of chloroform and methanol in a mixing ratio of 85:15 by weight, develop the color with iodine vapor, and compare the amount with a standard amount of a known amount to determine the qualitative determination of the contained material. went.
- Example 3 Measurement of Salt Resistance Effect (Evaluation as Surfactant)
- Example 4 Evaluation as resident ribosome in blood
- Lipids having the membrane composition ratios shown in Table 1 were weighed, dissolved in a mixture of black-mouth form and methanol (2: 1), and then evaporated with an evaporator. The organic solvent was distilled off, and the residue was further dried under reduced pressure for 1 hour. Next, to the dried lipid (lipid film) was added 1 Om1 of a 55 mM ammonium sulfate aqueous solution (pH 5.5) preheated to 65 ° C. And gently stirred (until the lipids came off the eggplant flask).
- This lipid dispersion was transferred to a homogenizer, homogenized for 10 strokes, and then sized using polycarbonate membrane filters of various pore sizes (0.2 / imX 3 times, 0.1 / xmX 3 times, 0.05 ⁇ mX 3 times, and 0 ⁇ 5 ⁇ mX 3 times). 03 ⁇ ⁇ 3 times) to prepare an empty ribosome dispersion having a particle diameter of about 100 nm.
- the empty ribosome dispersion liquid (total lipid concentration 50 mM) and doxorubicin solution (drug concentration: 3.3 mg / m 1 physiological saline) in which the above outer aqueous phase was replaced with physiological saline were previously heated to 60 ° C.
- the doxorubicin solution 6 was added to the empty ribosome dispersion 4 in a volume ratio (ie, the final drug concentration was 2.0 mg / ml and the final lipid concentration was 20 mM), the mixture was incubated at 60 ° C for 1 hour. Next, this was cooled at room temperature to obtain a doxorubicin-containing ribosome dispersion.
- each ribosome was around 100 nm.
- HSPC hydrogenated soy phosphatidylcholine
- HSPC hydrogenated soy phosphatidylcholine
- HSPC hydrogenated soy phosphatidylcholine
- HSPC hydrogenated soy phosphatidylcholine
- i3 ⁇ 4HSPC hydrogenated soy phosphatidylcholine
- i3 ⁇ 4DSPE Distearoynophosphatidinorecholine
- HSPC hydrogenated soy phosphatidylcholine: industrial applicability
- the phospholipid derivative of the present invention is highly safe for living organisms and is useful as a surfactant, solubilizer, or dispersant in the field of cosmetics and the like.
- the phospholipid derivative of the present invention which is a hyperbranched polyoxyethylene derivative
- lipid membrane structures such as ribosomes
- aggregation of fine particles in an aqueous medium can be achieved without destabilizing the lipid membrane structures.
- a stable solution state can be obtained.
- the ribosome containing the phospholipid derivative of the present invention is characterized by having excellent retention in blood.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003580347A JP4480402B2 (ja) | 2002-03-29 | 2003-03-28 | リン脂質誘導体 |
EP03715589.2A EP1498420B1 (fr) | 2002-03-29 | 2003-03-28 | Derive phospholipidique |
US10/508,704 US7495116B2 (en) | 2002-03-29 | 2003-03-28 | Phospholipid derivative |
AU2003220917A AU2003220917A1 (en) | 2002-03-29 | 2003-03-28 | Phospholipid derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002093694 | 2002-03-29 | ||
JP2002-93694 | 2002-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003082882A1 true WO2003082882A1 (fr) | 2003-10-09 |
Family
ID=28671762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/003966 WO2003082882A1 (fr) | 2002-03-29 | 2003-03-28 | Derive phospholipidique |
Country Status (5)
Country | Link |
---|---|
US (1) | US7495116B2 (fr) |
EP (1) | EP1498420B1 (fr) |
JP (1) | JP4480402B2 (fr) |
AU (1) | AU2003220917A1 (fr) |
WO (1) | WO2003082882A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1591447A1 (fr) * | 2003-01-06 | 2005-11-02 | Nof Corporation | Derives de phospholipides et procedes de leur production |
JP2008516056A (ja) * | 2004-10-08 | 2008-05-15 | アルザ コーポレイション | リポポリマーコンジュゲート |
US7399877B2 (en) | 2003-03-20 | 2008-07-15 | Nof Corporation | Phospholipid derivative |
US7531604B2 (en) | 2002-09-30 | 2009-05-12 | Nof Corporation | Phospholipid derivative |
WO2011059073A1 (fr) * | 2009-11-13 | 2011-05-19 | 日油株式会社 | Dérivé de phospholipide et liposomes réactifs au ph |
JP2013529237A (ja) * | 2010-05-20 | 2013-07-18 | ビーエーエスエフ ソシエタス・ヨーロピア | トリス(2−ヒドロキシフェニル)メタン誘導体並びにその製造及び使用法 |
JP2014189559A (ja) * | 2013-03-26 | 2014-10-06 | Nof Corp | 生分解性ポリオキシエチレン誘導体の製造方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
WO2006023444A2 (fr) | 2004-08-17 | 2006-03-02 | Tyco Healthcare Group, Lp | Barriere anti-adhesion |
CH715456B1 (de) | 2007-04-27 | 2020-04-30 | Mibelle Ag | Kosmetisches Produkt zur topischen Anwendung für den Schutz und die Erneuerung von Hautstammzellen, welches sich von dedifferenzierten Pflanzenzellen ableitet. |
US7666973B2 (en) | 2007-07-30 | 2010-02-23 | Tyco Healthcare Group Lp | Carbonate copolymers |
US20090048423A1 (en) * | 2007-08-15 | 2009-02-19 | Tyco Healthcare Group Lp | Phospholipid Copolymers |
US8268958B2 (en) | 2007-08-15 | 2012-09-18 | Tyco Healthcare Group Ip | Phospholipid copolymers |
CN103881084B (zh) * | 2014-03-14 | 2016-09-28 | 厦门赛诺邦格生物科技股份有限公司 | 一种支化聚乙二醇的磷脂类衍生物及其组成的脂质膜结构体 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06228012A (ja) * | 1993-01-29 | 1994-08-16 | Dai Ichi Seiyaku Co Ltd | リポソーム製剤 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US210618A (en) * | 1878-12-10 | Improvement in rod-adjusters for oil-wells | ||
US31481A (en) * | 1861-02-19 | Sewing-work holder | ||
US144247A (en) * | 1873-11-04 | Improvement in cultivating-plows | ||
US110436A (en) * | 1870-12-27 | Improvement in tidal motive-powers | ||
US5173219A (en) * | 1986-02-12 | 1992-12-22 | Research Development Foundation | Uniform spherical multilamellar liposomes of defined and adjustable size distribution |
JPH0651109B2 (ja) | 1987-03-09 | 1994-07-06 | 第一製薬株式会社 | 脂質膜構造体 |
JP2676854B2 (ja) * | 1988-12-16 | 1997-11-17 | 日本油脂株式会社 | ポリオキシアルキレン不飽和エーテルーマレイン酸エステル共重合体およびその用途 |
US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
CA2137297C (fr) | 1993-12-06 | 2000-04-18 | Tsuyoshi Miyazaki | Vesicule reactive et vesicule fonctionnelle fixee a une substance |
JP3620059B2 (ja) | 1994-03-04 | 2005-02-16 | 日本油脂株式会社 | 反応性小胞体、形成剤および機能性物質固定化小胞体 |
JP3480033B2 (ja) | 1994-03-31 | 2003-12-15 | 日本油脂株式会社 | ホスホリルコリン基又はその誘導体基含有共重合体、その製造法及び抗血栓性材料 |
JPH09255740A (ja) | 1996-03-26 | 1997-09-30 | Nof Corp | 三元共重合体 |
DE59805997D1 (de) * | 1997-08-18 | 2002-11-21 | Max Planck Gesellschaft | Phospholipidanaloge verbindungen |
GB9717905D0 (en) | 1997-08-22 | 1997-10-29 | Univ Aston | Lipid-containing compositions and uses thereof |
DE19835611A1 (de) | 1998-08-06 | 2000-02-10 | Max Planck Gesellschaft | Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten |
AU1787800A (en) | 1998-12-08 | 2000-06-26 | Phares Pharmaceutical Research N.V. | Phospholipid compositions |
EP1202714A1 (fr) | 1999-07-16 | 2002-05-08 | Purdue Research Foundation | Lipides d'ether vinyliques avec des groupes de tetes hydrophiles clivables |
EP1279406A4 (fr) | 2000-04-03 | 2007-10-24 | Santen Pharmaceutical Co Ltd | Transporteurs et systeme de distribution de medicament les utilisant |
DE60208454T2 (de) * | 2001-03-02 | 2006-09-07 | Nof Corp. | Polyalkylenoxid-modifizierte Phospholipide und Verfahren zu ihrer Herstellung |
AU2003266714A1 (en) | 2002-09-30 | 2004-04-19 | Daiichi Pharmaceutical Co., Ltd. | Phospholipid derivative |
CN100339382C (zh) | 2003-01-06 | 2007-09-26 | 日本油脂株式会社 | 磷脂质衍生物及其制造方法 |
JP4526479B2 (ja) | 2003-03-20 | 2010-08-18 | 日油株式会社 | リン脂質誘導体 |
-
2003
- 2003-03-28 EP EP03715589.2A patent/EP1498420B1/fr not_active Expired - Lifetime
- 2003-03-28 US US10/508,704 patent/US7495116B2/en not_active Expired - Lifetime
- 2003-03-28 AU AU2003220917A patent/AU2003220917A1/en not_active Abandoned
- 2003-03-28 JP JP2003580347A patent/JP4480402B2/ja not_active Expired - Fee Related
- 2003-03-28 WO PCT/JP2003/003966 patent/WO2003082882A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06228012A (ja) * | 1993-01-29 | 1994-08-16 | Dai Ichi Seiyaku Co Ltd | リポソーム製剤 |
Non-Patent Citations (4)
Title |
---|
ALLEN T.M. ET AL.: "Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1061, no. 1, 1991, pages 56 - 64, XP002970469 * |
REINER ZEISIG ET AL.: "Effect of sterical stabilization on macrophage uptake in vitro and thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1285, no. 2, 1996, pages 237 - 245, XP002970468 * |
See also references of EP1498420A4 * |
TSUTOMU YUDA ET AL.: "Prolongation of liposome circulation time by various derivatives of polyethyleneglycols", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 19, no. 10, 1996, pages 1347 - 1351, XP000633464 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7531604B2 (en) | 2002-09-30 | 2009-05-12 | Nof Corporation | Phospholipid derivative |
EP1591447A1 (fr) * | 2003-01-06 | 2005-11-02 | Nof Corporation | Derives de phospholipides et procedes de leur production |
US7524981B2 (en) | 2003-01-06 | 2009-04-28 | Nof Corporation | Phospholipid derivatives and process for the production there |
EP1591447A4 (fr) * | 2003-01-06 | 2009-11-11 | Nof Corp | Derives de phospholipides et procedes de leur production |
US7399877B2 (en) | 2003-03-20 | 2008-07-15 | Nof Corporation | Phospholipid derivative |
JP2008516056A (ja) * | 2004-10-08 | 2008-05-15 | アルザ コーポレイション | リポポリマーコンジュゲート |
WO2011059073A1 (fr) * | 2009-11-13 | 2011-05-19 | 日油株式会社 | Dérivé de phospholipide et liposomes réactifs au ph |
US8445712B2 (en) | 2009-11-13 | 2013-05-21 | Nof Corporation | Phospholipid derivative and pH-responsive liposomes |
JP2013529237A (ja) * | 2010-05-20 | 2013-07-18 | ビーエーエスエフ ソシエタス・ヨーロピア | トリス(2−ヒドロキシフェニル)メタン誘導体並びにその製造及び使用法 |
JP2014189559A (ja) * | 2013-03-26 | 2014-10-06 | Nof Corp | 生分解性ポリオキシエチレン誘導体の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2003082882A1 (ja) | 2005-08-04 |
EP1498420A1 (fr) | 2005-01-19 |
US20050220856A1 (en) | 2005-10-06 |
JP4480402B2 (ja) | 2010-06-16 |
EP1498420A4 (fr) | 2010-12-08 |
EP1498420B1 (fr) | 2017-02-01 |
AU2003220917A1 (en) | 2003-10-13 |
US7495116B2 (en) | 2009-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003082882A1 (fr) | Derive phospholipidique | |
EP0657463A1 (fr) | Dérivés de phospholipides et vésicule les contenant | |
CZ2002140A3 (cs) | Neutrální lipopolymer a lipozomové kompozice, které jej obsahují | |
EP1241172B1 (fr) | Derivés de phospholipides à chaîne oxyde de polyalkylene et leur methode de preparation | |
JP4540287B2 (ja) | ポリアルキレンオキシド修飾リン脂質の製造方法 | |
JP5515360B2 (ja) | 脂質誘導体 | |
JP2019151589A (ja) | 脂質ナノ粒子 | |
JP4710109B2 (ja) | ポリアルキレンオキシド修飾リン脂質、その製造方法および用途 | |
JP4403303B2 (ja) | リン脂質誘導体及びその製造方法 | |
JP4808403B2 (ja) | リン脂質誘導体 | |
JP4526479B2 (ja) | リン脂質誘導体 | |
KR20200025180A (ko) | 향상된 흡수력을 갖는 경피 흡수 마이셀 및 이를 포함하는 경피 흡수 조성물 | |
JPH07165770A (ja) | リン脂質誘導体 | |
EP4368657A1 (fr) | Dérivé lipidique sensible au ph | |
CN117534585A (zh) | 一种新型可电离阳离子脂质化合物及其制备方法与应用 | |
JPH092975A (ja) | 反応性小胞体形成剤および反応性小胞体 | |
JPH07165771A (ja) | 反応性小胞体および形成剤 | |
JPH07242681A (ja) | リン脂質誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003580347 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2003715589 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003715589 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003715589 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10508704 Country of ref document: US |